Payer Agreements Discussed in New FirstWord Report Recently Published at MarketPublishers.com

25 Nov 2011 • by Natalie Aster
Payer Agreements Discussed in New FirstWord Report Recently Published at MarketPublishers.com

LONDON – With tightening budgets and the contraction of payer funding for new products, it is getting more and more problematic for pharmaceutical companies to gain an access to the market.

Across the UK, the US, Canada, Australia and some European nations, payer schemes are becoming a common practice. Schemes advanced by pharmaceutical companies either aim to grapple financial issues such as price volume agreements, or they tackle uncertainty by addressing increased data collection. And the question arises – What are the key features that will ensure success?

New market research report “Payer Agreements: Splitting the Risk” worked out by FirstWord offers a complete and concise overview of payer schemes by definition and category.

Report Highlights:

  • detailed examination of the role of agreements in global pricing, reimbursement and market access;
  • discussion of the drivers for schemes, including health technology assessment (HTA) and financial challenges;
  • illustration of country-by-country trends along with case studies;
  • expert insight into the role of schemes and their evolution;
  • analysis of the pros and cons of agreements.

Report Details:

Title: Payer Agreements: Splitting the Risk
Published: October, 2011
Pages: 41
Price: US$ 695

Reports Contents:

EXECUTIVE SUMMARY

CURRENT AGREEMENTS WITH PAYERS ACROSS AUSTRALIA, EUROPE, CANADA AND THE US
Introduction
Defining and categorizing schemes
  Definitions from the literature
  UK definition and categorization
Drivers for schemes
  Financial challenges
  HTA and saying
no
  Dealing with uncertainty

COUNTRY TRENDS IN SCHEMES AND SELECTED CASE STUDIES
Australia
  Bosentan patient registry
Canada
  Clozaril money-back guarantee
Denmark
  No cure, no pay for Diovan
France
  Risperdal refund
Germany
  Aclasta refund scheme
Italy
  Tarceva discount scheme
  Sutent discount scheme
Serbia
  Avastin, Erbitux and MabCampath rebate schemes
Sweden
  Crestor and ezetimibe coverage with evidence development
UK
  Multiple Sclerosis Risk Sharing Scheme
  Velcade money back guarantee
  Lucentis dose capping scheme
US
  Proscar refund scheme
  Zocor refund scheme
  Januvia guarantee scheme
  Sanofi and Proctor & Gamble pay for fractures scheme

POTENTIALS AND PITFALLS OF AGREEMENTS
Fit with pricing and reimbursement environments
Pros and cons
Reality check

CONCLUSIONS
Too early to say
Maybe necessary, but not sufficient
Exploring uncertainty, not discounting in the future

ACKNOWLEDGEMENTS

More new research reports by the publisher can be found at FirstWord page.

 

CONTACTS

The Market Publishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970

ps@marketpublishers.com

MarketPublishers.com